相似文献
1
Location, location, location: contrasting roles of synaptic and extrasynaptic NMDA receptors in Huntington's disease.
Neuron. 2010 Jan 28;65(2):145-7. doi: 10.1016/j.neuron.2010.01.010.
2
GluN3A promotes NMDA spiking by enhancing synaptic transmission in Huntington's disease models.
Neurobiol Dis. 2016 Sep;93:47-56. doi: 10.1016/j.nbd.2016.04.001. Epub 2016 Apr 9.
3
Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice.
Neuron. 2010 Jan 28;65(2):178-90. doi: 10.1016/j.neuron.2010.01.008.
4
Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.
J Physiol. 2007 Dec 15;585(Pt 3):817-31. doi: 10.1113/jphysiol.2007.142448. Epub 2007 Oct 18.
5
Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function.
Mol Cell Neurosci. 2011 Dec;48(4):308-20. doi: 10.1016/j.mcn.2011.05.001. Epub 2011 May 7.
6
Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models.
Nat Med. 2013 Aug;19(8):1030-8. doi: 10.1038/nm.3246. Epub 2013 Jul 14.
7
Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
J Neurosci Res. 2005 Nov 1;82(3):377-86. doi: 10.1002/jnr.20651.
8
Hunting for excitement: NMDA receptors in Huntington's disease.
Neuron. 2002 Mar 14;33(6):841-2. doi: 10.1016/s0896-6273(02)00631-1.
9
Restored Fyn Levels in Huntington's Disease Contributes to Enhanced Synaptic GluN2B-Composed NMDA Receptors and CREB Activity.
Cells. 2022 Sep 29;11(19):3063. doi: 10.3390/cells11193063.
10
Mechanisms of synapse-to-nucleus calcium signalling in striatal neurons and impairments in Huntington's disease.
J Neurochem. 2024 Sep;168(9):2671-2689. doi: 10.1111/jnc.16132. Epub 2024 May 21.
引用本文的文献
1
Excitotoxicity, Oxytosis/Ferroptosis, and Neurodegeneration: Emerging Insights into Mitochondrial Mechanisms.
Aging Dis. 2024 Aug 8. doi: 10.14336/AD.2024.0125-1.
2
C57BL/6 Background Attenuates mHTT Toxicity in the Striatum of YAC128 Mice.
Int J Mol Sci. 2021 Nov 23;22(23):12664. doi: 10.3390/ijms222312664.
3
Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease.
Neurosci Bull. 2020 Nov;36(11):1299-1314. doi: 10.1007/s12264-020-00582-8. Epub 2020 Oct 7.
4
Building a Bridge Between NMDAR-Mediated Excitotoxicity and Mitochondrial Dysfunction in Chronic and Acute Diseases.
Cell Mol Neurobiol. 2021 Oct;41(7):1413-1430. doi: 10.1007/s10571-020-00924-0. Epub 2020 Jul 22.
5
The Effects of General Anesthetics on Synaptic Transmission.
Curr Neuropharmacol. 2020;18(10):936-965. doi: 10.2174/1570159X18666200227125854.
6
Calcium-Handling Defects and Neurodegenerative Disease.
Cold Spring Harb Perspect Biol. 2020 Jul 1;12(7):a035212. doi: 10.1101/cshperspect.a035212.
7
Therapeutic approaches to Huntington disease: from the bench to the clinic.
Nat Rev Drug Discov. 2018 Oct;17(10):729-750. doi: 10.1038/nrd.2018.133. Epub 2018 Sep 21.
8
Calcium signaling and molecular mechanisms underlying neurodegenerative diseases.
Cell Calcium. 2018 Mar;70:87-94. doi: 10.1016/j.ceca.2017.06.008. Epub 2017 Jun 30.
9
Enhancement of postsynaptic GABAA and extrasynaptic NMDA receptor-mediated responses in the barrel cortex of Mecp2-null mice.
J Neurophysiol. 2016 Mar;115(3):1298-306. doi: 10.1152/jn.00944.2015. Epub 2015 Dec 16.
10
Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases.
Front Cell Neurosci. 2015 Mar 2;9:25. doi: 10.3389/fncel.2015.00025. eCollection 2015.
本文引用的文献
1
Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice.
Neuron. 2010 Jan 28;65(2):178-90. doi: 10.1016/j.neuron.2010.01.008.
2
Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin.
Nat Med. 2009 Dec;15(12):1407-13. doi: 10.1038/nm.2056. Epub 2009 Nov 15.
3
Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease.
J Neurosci. 2009 Aug 19;29(33):10371-86. doi: 10.1523/JNEUROSCI.1592-09.2009.
4
Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity.
Science. 2009 Jun 5;324(5932):1327-30. doi: 10.1126/science.1172871.
5
Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease.
J Neurosci. 2009 Feb 25;29(8):2414-27. doi: 10.1523/JNEUROSCI.5687-08.2009.
6
The dichotomy of NMDA receptor signaling.
Neuroscientist. 2007 Dec;13(6):572-9. doi: 10.1177/10738584070130060401.
7
N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.
Prog Neurobiol. 2007 Apr;81(5-6):272-93. doi: 10.1016/j.pneurobio.2006.11.003. Epub 2006 Dec 22.
8
The corticostriatal pathway in Huntington's disease.
Prog Neurobiol. 2007 Apr;81(5-6):253-71. doi: 10.1016/j.pneurobio.2006.11.001. Epub 2006 Dec 13.
9
A pilot study of the clinical efficacy and safety of memantine for Huntington's disease.
Parkinsonism Relat Disord. 2007 Oct;13(7):453-4. doi: 10.1016/j.parkreldis.2006.08.005. Epub 2006 Oct 13.
10
Glutamate leakage from a compartmentalized intracellular metabolic pool and activation of the lipoxygenase pathway mediate oxidative astrocyte death by reversed glutamate transport.
Glia. 2006 Jul;54(1):47-57. doi: 10.1002/glia.20353.
Zotero 插件